Patient-reported and Clinical Outcomes in Adults With Relapsed or Refractory Hodgkin's Lymphoma Receiving Brentuximab Vedotin: a Multicenter, Prospective, Observational Study in a Real World Setting
Phase of Trial: Phase IV
Latest Information Update: 01 Nov 2019
Price : $35 *
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 25 Oct 2019 Status changed from not yet recruiting to recruiting.
- 21 Mar 2018 Planned initiation date changed from 1 Mar 2018 to 31 Mar 2018.
- 27 Feb 2018 New trial record